Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Antares Pharma: Acquisition by Halozyme

I am a little sad to see Antares sell out to Halozyme. I thought that the rubber was just starting…
Read more…

Antares: The Future Looks Really, Really Bright (ATRS, Buy, $4.18)

Investment Thinking

The fourth quarter conference call was very encouraging to me. The investment thesis is coming together much better and…
Read more…

Antares: Encouraging Revenue Guidance (ATRS, Buy, $4.00)

Key Point

I think that the stock has the potential to double in 2021.

New Revenue Guidance

Antares has just issued guidance…
Read more…

Antares: Xyosted Sales Projections for 2020 Through 2023 (ATRS, Buy, $2.62)

Sales Projections for Xyosted

Xyosted just completed its sixth full quarter of sales since its launch in 4Q, 2018. Almost all…
Read more…

Why Bother with Antares? (ATRS, Buy, $2.86)

Investment Perspective

Periodically, I get a comment from one subscriber regarding Antares to the effect of why are you bothering…
Read more…

Antares (ATRS, Buy, $2.72) Effect of Covid-19 Appears Modest So Far On Company and Xyosted in Particular

Investment Overview

Antares stock has been more impacted by the market sell off than many other biotechnology stocks which have rebounded…
Read more…

Antares: Detailed Sales and Earnings Projections for 2020, 2021 and 2022 (ATRS, Buy, $4.86)

Objective of This Report

Antares is an extremely difficult company to model on a sales and earnings basis. Its core technology…
Read more…

Antares Pharma: Highlights from Presentation at Jefferies Healthcare Conference: (ATRS, Buy, $4.79)

Purpose of Report

I just listened to the presentation by Antares at the Jefferies conference in London on Wednesday, November 20…
Read more…

Antares Pharmaceuticals: Projecting Very Strong Growth in Xyosted Sales for 2020, 2021 and 2022 (ATRS, Buy, $3.89)

Key Points

In my sales and earnings model for 2020, I will be using a working estimate of $53.6 million…
Read more…

Antares Pharma: Quick Take on Implication of 3Q Results for Future Growth (ATRS, Buy, $3.70)

Key Points:

Xyosted launch continues to impress. Projecting sales of $22 million in 2019 and over $50 million in 2019

Read more…

AMAG Pharmaceuticals (AMAG, $12.20); Antares (ATRS, Buy, $3.59) What Will FDA AdCom Recommend on Makena in the Aftermath of Failed Prolong Trial?

Key Conclusions

I believe that there is a 95% probability that Makena will remain on the market and only a 5%…
Read more…

Antares: Impressive Xyosted Prescription Trends Continue (ATRS, Buy, $3.30)

Key Points:

Xyosted prescription trends remain impressive and based on audit data for the last 11 weeks, there has been…
Read more…

Antares: Update on Sales Projections for Xyosted (ATRS, $3.30, Buy)

Investment Thesis

I have seen seven plus months of data on prescription trends for Xyosted as estimated by the prescription auditing…
Read more…

Antares: Highlights from 2Q, 2019 Conference Call (ATRS, $3.29, Buy)

Introduction

I have heard encouraging comments on my recently announced approach of doing shorter, less pedantic reports on new companies. This…
Read more…

Antares Pharma: The Xyosted Launch Continues to Look Good (ATRS, Buy, $3.37)

Investment Thesis

The cornerstone of my positive investment thesis for Antares is Xyosted, which was fully launched in January 2019. While…
Read more…

Antares Pharma: Detailed Sales and Earnings Model Through 2021 (ATRS, $2.85, Buy)

Investment Thesis

Recently, I have received a couple of sarcastic comments to the effect that this stock has gone nowhere for…
Read more…

Antares Pharma: The Xyosted Launch Looks Like it will Meet or Beat Wall Street Expectations for 2019 (ATRS, Buy, $2.90)

Investment Thesis

The cornerstone of my positive investment thesis for Antares is Xyosted, which was fully launched in January 2019. While…
Read more…

Antares: Tracking Report on Xyosted Prescriptions (ATRS, Buy, $2.88)

Introduction and Overview

I have obtained access to weekly prescription trends for Xyosted which I will publish periodically. Marketing began on…
Read more…

Antares (ATRS, Buy, $3.51); AMAG Pharmaceuticals (AMAG, $11.73) First Thoughts about How the PROLONG Study Could Affect Makena Usage

Introduction

On Friday, the PROLONG clinical study was released that showed no difference in outcomes between Makena and placebo. This was…
Read more…

Antares: Sales Growth Guidance for 2019 is Extremely Bullish (ATRS, $3.60, Buy)

Antares just reported
4Q, 2018 sales and earnings. I will do a more detailed analysis of the Company
sometime after the release…
Read more…

Antares: Multiple New Product Launches Make for Extreme Complexity in Earnings Forecasts for 2019 to 2021 (ATRS, Buy, $3.59)

Investment Thesis in Brief:

In this report, I have put together an earnings forecast projecting EPS of (0.04) in 2019, $0.19…
Read more…

Antares: Xyosted is Approved; Let the Good Times Roll (ATRS, Buy, $3.77)

Investment Thesis

At Last, Three Major Product Approvals in 2018

It has been a torturous wait for Antares’ very promising pipeline to…
Read more…

Antares: Investment Story has Shifted from Pipeline Promise to Commercial Potential (ATRS, $3.74, Buy)

Investment Summary

At long last, the exciting new product potential of Antares is becoming a commercial reality. A very significant milestone…
Read more…

Antares Pharma: Approval of Xyosted on or before September 29, 2018 Is Highly Probable (ATRS, Buy, $2.12)

Background on Xyosted NDA Resubmission Following Complete Response Letter

The original PDUFA date for the Xyosted NDA was October 20, 2017,…
Read more…

Antares: FDA Comments from Type A Meeting Are a Best Case Outcome for Xyosted (ATRS, $2.13, Buy)

Management Comments on Type A Meeting

Antares released the following comment on March 27, 2018 that deals with the Complete Response…
Read more…

Antares: Things Are Looking Up (ATRS, Buy, $2.22)

Overview of Report

I listened to the presentation by CEO Bob Apple at the Raymond James conference on March 5th and…
Read more…

Antares Pharma: Makena SC Approval is a Big Positve; There are more Approvals to Come (ATRS, Buy, $2.35)

Investment Thesis

Finally, the FDA comes through with the approval for Makena SC. My Buy recommendation on Antares is based on…
Read more…

Antares Pharma: Update on Xyosted (ATRS, Buy, $2.34)

Regulatory Update

Antares announced that it has scheduled a Type A meeting with FDA for Xyosted which is intended to resolve…
Read more…

Antares' Response to Complete Response Letter on Xyosted is in Line with My Expectations (ATRS, Buy, $2.05)

Antares Pharma announced on December 21st that it had submitted a request to the FDA for a type A meeting…
Read more…

Antares Pharma: My Hypothesis on Issues that Resulted in the CRL for Xyosted and Potential Timing of Approval (ATRS. Buy, $1.63)

Investment Thesis

Xyosted is viewed by investors as the most important product in Antares” broad pipeline. In anticipation of approval…
Read more…

Antares: Approval of Xyosted is a Matter of When, Not If (ATRS, $2.12, Buy)

The Issue

Antares received a complete response letter for Xyosted that did not cite any questions relating to efficacy, manufacturing, quality…
Read more…

Antares Pharma: FDA Action to not Approve Xyosted on its October 20, 2017 PDUFA Date is Perplexing (ATRS, Buy, $2.23)

Overview

Investors have had high confidence that Xyosted would be approved by the FDA on its October 20, 2017 PDUFA date.…
Read more…

Antares Pharma: This Small, Emerging Biotechnology Company Is Poised for Explosive Growth Based on Five Major New Product Introductions by 2020 (ATRS, Buy, $3.02

Investment Thesis

Antares is one of my top recommendations based on its extremely impressive pipeline prospects. In a March 23, 2017…
Read more…

Antares: AMAG Submits Supplemental New Drug Application to FDA for Makena® Auto-Injector for Subcutaneous Use: (Antares (ATRS, Buy, $2.86)

AMAG announced on April17, 2017 that it had submitted a sNDA for the Makena Auto-Injector. This was in line with…
Read more…

Antares: Pipeline is Bursting with Late Stage Products (ATRS, $2.77, Buy)

Key Points:

Antares has an impressive portfolio of seven new products that could lead to explosive growth over the next…
Read more…

AMAG Pharmaceuticals: Will FDA Approve Makena SC (AMAG, Neutral, $21.75)

Importance of Makena SC to AMAG?

AMAG is engaged in a high stakes clinical development program in which it is endeavoring…
Read more…

AMAG and Antares: Update on the Development of Makena SC (AMAG, Neutral, $24.40) (ATRS, Buy, $2.04)

Key Points:

Recent announcement that AMAG will not pursue Orphan Drug Exclusivity for Makena SC has hammered the stock of…
Read more…

SmithOnStocks Top Stock Picks for 2017, January 3, 2017

Purpose of this Report

I last summarized my stock recommendations in a September 12, 2016 report. There has been little change…
Read more…

Antares: Teva Projects Launch of AB Rated Generic to EpiPen in Early 2018 (ATRS, Buy, $1.87)

Eyal Desheh is the Chief Financial Officer of Teva. During the recent third quarter conference call, he answered a question…
Read more…

Antares: Some Key Points from 3Q, 2016 Conference Call (ATRS, Buy, $1.84)

Investment Opinion

In my opinion, Antares is substantially undervalued. My price target is $6 60 in 2018. The thinking behind this…
Read more…

Antares: Updates on QST and AB Generic to EpiPen; Reiteration of Buy Recommendation (ATRS, Buy, $1.65)

Overview and Investment Opinion

In my opinion, Antares is substantially undervalued. My price target is $6 60 $8 in 2018 and…
Read more…

Antares; Are Mylan's Woes A Potential Positive for AB Rated Generic to EpiPen (ATRS, $1.37, Buy)

You cannot turn on the business news channels without hearing extensive comments and condemnation by pundits and politicians about Mylan's aggressive…
Read more…

Antares: Comment on Strength in the Stock Price (ATRS, $1.29, Buy)

A number of people have asked me if I know of any specific reason for the strength in Antares's stock…
Read more…

Antares Pharmaceuticals: Teva Launches AB Generic to Imitrex (ATRS, Buy, $1.06)

Teva announced today the launch of its AB rated generic to Imitex (sumatriptan). Remember that Antares books revenues from Teva…
Read more…

Antares Pharmaceuticals: Highlights on Makena from AMAG Pharmaceuticals Analyst Day (ATRS, $1.14, Buy)

Report Overview

Antares and AMAG Pharmaceuticals are jointly developing a new subcutaneous formulation of AMAG’s key drug Makena which is currently…
Read more…

Antares: Presentation Highlights from Deutsche Bank Conference (ATRS, Buy, $0.97)

Overview

I listened to CEO Bob Apple speak at the Deutsche Bank conference and wanted to pass along a few pieces…
Read more…

Antares: AMAG Issues Guidance on Timing of Subcutaneous Makena (ATRS, Buy, $1/05)

I recently wrote a report on Antares entitled Makena has the Potential to Make a Very Significant Contribution to EPS  that…
Read more…

Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 (ATRS, Buy, $0.92)

Investment Thesis in Brief

If you like numbers, you will like this report. It is a very detailed analysis of the…
Read more…

Antares: Makena Has the Potential to Make a Very Significant Contribution to EPS (ATRS, $0.85. Buy)

Investment Thesis
Investment Overview

The launch of Otrexup has been extremely disappointing in contrast to my high expectations. Medac launched a competitive…
Read more…

Antares: Disappointing News on AB Rated Version of EpiPen (ATRS, $0.95)

Investment Perspective

Teva filed a 6-K regulatory document last night that stated: “Teva received a complete response letter on February 23, 2016 relating…
Read more…

Antares: Undeterred by the Poor Stock Performance I Continue to Pound the Table (ATRS. Buy, $1.30)

Upcoming Catalysts

This is a detailed note updating my thinking on Antares and discussing how I come up with my 2017…
Read more…

Antares: An Update on My Investment Thinking (ATRS, Buy, $1.33)

Investment Thesis

This has been a very disappointing year for Antares investors; the stock closed at $2.57 on December 31, 2014…
Read more…

Antares: The Stock Price Does Not Reflect the Fundamentals (ATRS, $1.60, Buy)

Introduction

Antares recently updated its corporate presentation on their website. .There were several slides in the presentation that reinforce my confidence…
Read more…

Quick Take on Antares Following 2Q, 2015 Conference Call (ATRS, Buy, $2.10)

Investment Opinion

Antares stock has been pummeled by the “so far” disappointing launch of Otrexup and uncertainty as to when or…
Read more…

Antares: One of My Top Stock Picks for 2015 and 2016 (ATRS, Buy, $2.40, For Paid Subscribers)

Introduction to Report

One of my assets is also one of my biggest drawbacks. When I am writing on a Company…
Read more…

Comments on Antares, Kite Pharma and Northwest Biotherapeutics

SmithOnStocks Mailbox
About the Mailbox:

My mailbox comments are brief articles on stocks in which I am involved. These can come from…
Read more…

Antares: Teva Offer to Buy Mylan Should Have No Effect on Launch of AB Rated Generic to EpiPen (ATRS, $2.76, Buy)

Overview

Subsequent to my posting of my recent update on Antares, I have seen that Teva has made an offer to…
Read more…

Antares: Detailed Sales and Earnings Projections for 2015 and 2016 (ATRS, Buy, $2.77, subscription required)

Investment Thesis
I continue with my long standing recommendation on Antares. Last year was a disappointing year for the stock, but…
Read more…

Antares Pharmaceuticals: Highlights of Presentation at JP Morgan Conference (ATRS, $2.36. Buy)

Investment Overview

Antares has hit a somewhat dis-settling stretch as Otrexup prescriptions have recently flattened and the FDA recommended that additional…
Read more…

Delay in Quick Shot Testosterone Clinical Program is Not a Major Setback for the Stock (ATRS, Buy, $2.53)

Antares sent out a press release today about a new development in the Quick Shot Testosterone phase 3 program. The Company…
Read more…

Antares: Responding to Two Questions on Teva’s AB Rated Competitor to EpiPen (ATRS, Buy, $2.44)

Purpose of the Blog

I very much appreciate questions and feedback from subscribers to my website. I have had two recent…
Read more…

Antares: 2015 Could Be the Breakout Year for the Stock (ATRS, $2.24, Buy)

I project 2015 sales of Otrexup at $22 million; if so, it would be generating profit in the latter half…
Read more…

Antares: Although it is Still Early, I Think That Otrexup Launch is Going Very Well (ATRS, Buy, $2.93, Paid subscribers)

Investment Thesis

The broad based business model of Antares results in its receiving revenues from numerous products that are marketed by…
Read more…

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction

The recent sharp market correction and rotation out of growth stocks like biotechnology and technology…
Read more…

Antares (ATRS, Buy, $4.00) Why I Think That the Otrexup Launch Will Be A Success (Paid Subscribers Only)

Recent Price Behavior

Antares’ (ATRS) price has drifted down since the approval of Otrexup for the treatment of rheumatoid arthritis and…
Read more…

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

What SmithOnStocks Is All About
It is traditional at the start of the year to go over stock picks for the…
Read more…

Antares Marketing Agreement on Otrexup with Leo is a Nice Positive (ATRS, $3.93)

Antares is preparing to launch Otrexup for rheumatoid arthritis in the US in late January of 2014 with its own…
Read more…

Antares: Thoughts on the Upcoming Otrexup Launch (ATRS, $3.64)

Investment Thesis
Antares is preparing to launch Otrexup in January 2014; it is the first product it has ever introduced and…
Read more…

Antares: An In-Depth Look at Otrexup and Re-iteration of My Buy Recommendation (ATRS: $4.45) (Paid Subscribers Only)

Investment Overview and Thesis
Antares has carved out an interesting niche in the pharmaceutical industry through building a drug delivery business…
Read more…

SmithOnStocks Opines on Stocks May 19, Edition

One Approach for Investing in Emerging Biotechnology Stocks
I write on biotechnology and pharmaceutical companies of all sizes, but I have…
Read more…

Antares: Reiteration of My Buy Recommendation (ATRS, $4.00)

Investment Thesis
It has been some time since I have written on Antares (ATRS); in fact my last note was in…
Read more…

Antares' Pipeline is Bursting with New Products; Vibex MTX is the Star (ATRS)

Investment Opinion
I am reiterating my Buy recommendation on Antares which was initiated on December 6, 2011 at a price of…
Read more…

Antares: Settlement of Litigation on EpiPen is a Positive (AIS, $3.08)

Conclusion
I believe that the settlement on the EpiPen litigation is a positive for Antares. It pushes the launch date for…
Read more…

Vibex MTX is the Most Exciting Component of the Antares Investment Outlook (AIS, $2.74)

Investment Thesis
I initiated coverage of Antares (AIS) on December 8, 2011 with a buy rating. Important factors driving my recommendation…
Read more…

The Promise of the Antares Pipeline is the Basis of my Buy Recommendation (AIS, $2.40)

Investment Opinion
The failure of the Libi-Gel trial rocked the stock of Antares (AIS) and caused it to drop from around…
Read more…

Antares Is Initated As A Buy Based On Broad, Promising Pipeline (AIS, $2.59)

Investment Opinion
I am recommending purchase of Antares (AIS) at the current level of $2.59. My 2015 price target is $6.70.…
Read more…

Libi-Gel Phase III Trial Results Should Be Released Shortly (AIS, $2.73)

Investment Overview
One of the eleven products that Antares has in late stage development is Libi-Gel for treating female sexual dysfunction…
Read more…

Collaboration with Teva on Self-Injected Drugs Is the Major Driver of the Investment Thesis (AIS, $2.68)

Investment Thesis
In my initial report on Antares, I recommended purchase based importantly on the potential for its self-injection technology. One…
Read more…

Approval of Anturol Is Significant Positive (AIS, $2.68)

Anturol Approval is A Major Positive

Recently, I wrote a note about Anturol discussing its therapeutic profile and the commercialization agreement…
Read more…

Anturol's December 8th PDUFA Date Is Looming (AIS, $2.77)

Introduction
I recently began coverage of Antares with a buy. The basis of my recommendation was the exceptional pipeline of drugs…
Read more…

Antares Initiated As A Buy (AIS, $2.59)

Investment Opinion
I am recommending purchase of Antares (AIS) at the current level of $2.59. My 2015 price target is $6.70.…
Read more…